Our goal is to develop a better understanding of HIV-1 immunopathogenesis and new immune-based strategies of anti-HIV therapy that are better tolerated and more sustainable for patient populations than the life-long use of antiretroviral therapy.
The Montaner laboratory is investigating mechanisms of disease in HIV-1 infection and novel approaches to augment immune function by combining virological and immune-based research on patient-derived material as well as by using laboratory models of virus infection. The work is focused on 1) regulation of innate immunity, 2) identifying new mechanisms of immunodeficiency and discovering new approaches to reverse them, 3) exploring new therapy management practices, and 4) understanding the relationship between immune antiviral responses and control of HIV-1 infection.
Current Research Activities and Interests
Innate Immunity & HIV-1 Infection: Dendritic cells & Natural Killer Cells Direct or indirect interactions of viral particles with innate and specific adaptive immunity effector cells affects the cross talk between antigen presenting cells (APCs), NK cells and the antigen specific T and B-lymphocytes, and may contribute to regulate HIV disease progression. Specifically, we are pursuing analysis of the effects of HIV infection in macrophages, dendritic cells and Natural Killer cells.
A relationship between levels of HIV replication and innate cell function is supported by our preliminary data on DC and NK subset changes and viral replication in HIV-infected individuals showing an impairment of NK cell responses, APC endocytic uptake, differential expression of cell surface molecules associated with APC function, increased APC apoptosis, decreased IL-12 secretion, decreased IFN-? secretion and a loss of plasmacytoid dendritic cells (PDCs) and myeloid dendritic cells (MDCs) in PBMC. Based on these observations and the observed effects of antiretroviral therapy on DC and NK cell subsets, the inverse correlation between viral load and DC subsets in untreated HIV positive subjects and our observations of augmented NK lytic activity by activated DC, we are addressing longitudinal analysis and mechanistic experiments on DC/HIV interactions to test the hypothesis that HAART-mediated viral suppression restores mature NK and DC subsets necessary to activate innate mechanisms of antiviral control through lysis of infected cells. The long-term goal of this area of focus is to define the contribution of two major components of the innate immune system (accessory and Natural Killer cells) in controlling HIV replication thereby modifying disease progression. The short-term goal of our effort is to address the consequences of immune reconstitution on innate immunity following antiretroviral therapy, with particular emphasis on correlates of DC and NK cell functions and the consequences of HIV interactions with DC subsets. While adaptive HIV-specific immune responses continue to be an area of active investigation in AIDS research, the potential contribution of innate immune response, such as the relationship between DC subsets, disease progression and its consequences on other innate functions such as NK function remains largely unexplored in HAART settings. This study represents a hypothesis-driven collaborative effort by The Wistar Institute, the Infectious Disease Division of the University of Pennsylvania Hospital, Philadelphia FIGHT, Schering-Plough, Becton Dickinson, The Women's Interagency Study Cohort and the Multiple AIDS Cohort Study (MACS).
Demers A, Kang G, Ma F, Lu W, Yuan Z, Li Y, Lewis M, Kraiselburd EN, Montaner L, Li Q: The Mucosal Expression Pattern of Interferon-ε in Rhesus Macaques J Leukoc Biol Aug 2014 Notes: Epub ahead of print.
Tomescu C, Ross BN, Lynn K, Mounzer KC, Kostman JR, Montaner LJ : A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers. PLoS One 9(7): e103209, Jul 2014.
Abdulhaqq S, Martinez MI, Kang G, Foulkes AS, Rodriguez IV, Nichols SM, Hunter M, Sariol C, Ruiz LA, Ros, BN, Yin X, Speicher DW, Haase A, Marx PA, Li Q, Kraiselburd E, Montaner LJ: Serial Cervicovaginal Exposures With Replication-Deficient SIVsm Induce Higher Dendritic Cell (pDC) and CD4+ T-Cell Infiltrates Not Associated With Prevention but a More Severe SIVmac251 Infection of Rhesus Macaques J Acquir Immune Defic Syndr 65(4): 405-13, Apr 2014.
Dawany N, Showe LC, Kossenkov AV, Chang C, Ive P, Conradie F, Stevens WS, Sanne I, Azzoni L, Montaner LJ: Identification of a 251 Gene Expression Signature that Can Accurately Detect M. tuberculosis in Patients with and with HIV Co-infection. PLos One 9(2): e89925, Feb 2014.
Gekonge B, Bardin MC, Montaner LJ: Nitazoxanide inhibits HIV viral replication in monocyte-derived macrophages. AIDS Res Hum Retroviruses 2014 Notes: In Press.
Sierra-Madero JG, Ellenberg S, Rassool MS, Tierney A, Belaunzaran-Zamudio PF, Lopez-Martinez A, Pineirua-Menendez A, Montaner LJ, Azzoni L, Rivera BC, Sereti I, Andrade-Villanueva J, Mosqueda-Gomez JL, Rodriguez B, Sanne I, Lederman MM, the CADIRIS Study Team.: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution of Inflammatory Syndrome in HIV-Infection: The CADIRIS Study. Lancet Inf Dis 2014 Notes: In Press.
Stevenson JP, Kindler HL, Jacobs-Small M, Hull J, Schwed D, Ranganathan A, Papasavvas E, Montaner LJ, Sun J, Heitjan DF, Langer CJ, McPherson JM, Albelda SM : Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology 2(8): e26218, Aug 2013.
Chhatre S, Metzger DS, Frank I, Boyer J, Thompson E, Nidich S, Montaner LJ, Jayadevappa R: Effects of behavioral stress reduction Transcendental Meditation intervention in persons with HIV AIDS Care 25(10): 1291-7, Feb 2013.
Tebas P, Stein D, Binder-Scholl G, Mukherjee R, Brady T, Rebello T, Humeau L, Papasavvas E, Montaner LJ, Schullery D, Shaheen F, Brennan AL, Zheng Z, Cotte J, Slepushkin V, Veloso E, Mackley A, Hwang WT, Aberra F, Zhan J, Boyer J, Collman RG, Bushman FD, Levine BL, June CH: Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long anti-sense to HIV. Blood 121(9): 1524-33, Feb 2013.
Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, Busch MP, Deeks SG, Carrington M, O'Doherty U, Kostman J, Montaner LJ : Pegylated Interferon-α2A mono-therapy results in suppression of HIV-1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 207(2): 213-22, Jan 2013.
back to top
Last updated: 10/15/2014
The Trustees of the University of Pennsylvania